Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification

Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of the anterior horn cells of the spinal cord, causing symmetric proximal muscle weakness. SMA is classified in three clinical types, SMA I, SMA II, and SMA III, based on the severity of the symptoms and th...

Full description

Saved in:

Bibliographic Details
Published in:	Neurogenetics 2006-11, Vol.7 (4), p.269-276
Main Authors:	SCARCIOLLA, Oronzo, STUPPIA, Liborio, GRAMMATICO, Parla, GIACANELLI, Manio, ROSATELLI, Maria Cristina, UNCINI, Antonino, DALLAPICCOLA, Bruno, DE ANGELIS, Maria Vittoria, MURRU, Stefania, PALKA, Chiara, GIULIANI, Rossella, PACE, Marta, DI MUZIO, Antonio, TORRENTE, Isabella, MORELLA, Annunziata
Format:	Article
Language:	eng
Subjects:	Adult Aged Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases DNA Probes Fundamental and applied biological sciences. Psychology Gene Dosage Genes Genetic disorders Genetics of eukaryotes. Biological and molecular evolution Genotype Genotype & phenotype Heterozygote Humans Medical sciences Middle Aged Molecular and cellular biology Neurology Polymerase Chain Reaction - methods Polymorphism Polymorphism, Restriction Fragment Length Risk Factors Spinal cord Spinal Muscular Atrophies of Childhood - epidemiology Spinal Muscular Atrophies of Childhood - genetics Vertebrates: nervous system and sense organs
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of the anterior horn cells of the spinal cord, causing symmetric proximal muscle weakness. SMA is classified in three clinical types, SMA I, SMA II, and SMA III, based on the severity of the symptoms and the age of onset. About 95% of SMA cases are caused by homozygous deletion of the survival motor neuron 1 (SMN1) gene (5q13), or its conversion to SMN2. The molecular diagnosis of this disease is usually carried out by a polymerase chain reaction-restriction fragment length polymorphism approach able to evidence the absence of both SMN1 copies. However, this approach is not able to identify heterozygous healthy carriers, which show a very high frequency in general population (1:50). We used the multiple ligation-dependent probe amplification (MLPA) approach for the molecular diagnosis of SMA in 19 affected patient and in 57 individuals at risk to become healthy carriers. This analysis detected the absence of the homozygous SMN1 in all the investigated cases, and allowed to discriminate between SMN1 deletion and conversion to SMN2 on the basis of the size showed by the peaks specific for the different genes mapped within the SMA critical region. Moreover, MLPA analysis evidenced a condition of the absence of the heterozygous SMN1 in 33 out of the 57 relatives of the affected patients, demonstrating the usefulness of this approach in the identification of healthy carriers. Thus, the MLPA technique represents an easy, low cost, and high throughput system in the molecular diagnosis of SMA, both in affected patients and in healthy carriers.
ISSN:	1364-6745 1364-6753